Zobrazeno 1 - 10
of 807
pro vyhledávání: '"Talazoparib"'
Publikováno v:
Cancer Management and Research, Vol Volume 16, Pp 1267-1283 (2024)
Bicky Thapa,1,* Navonil De Sarkar,2– 4,* Subhajit Giri,2,3 Komal Sharma,2– 4 Mingee Kim,5 Deepak Kilari1 1Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; 2Medical College of Wisconsin Cancer Center,
Externí odkaz:
https://doaj.org/article/7099d4bb6250439690b805dadd42278b
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Breast cancer is one of the tumors with the highest prevalence rate among women in the world, and its BRCA1/2 gene is a common mutation site. Talazoparib, as a targeted PARP inhibitor, can effectively control the occurrence and development o
Externí odkaz:
https://doaj.org/article/b87b8e5d528f477c9277ae5625db7a82
Autor:
Xiaonan Zhang, Natallia Rameika, Lei Zhong, Verónica Rendo, Margus Veanes, Snehangshu Kundu, Sandro Nuciforo, Jordan Dupuis, Muhammad Al Azhar, Ioanna Tsiara, Pauline Seeburger, Shahed Al Nassralla, Viktor Ljungström, Richard Svensson, Ivaylo Stoimenov, Per Artursson, Markus H. Heim, Daniel Globisch, Tobias Sjöblom
Publikováno v:
EBioMedicine, Vol 109, Iss , Pp 105368- (2024)
Summary: Background: Loss of heterozygosity (LOH) diminishes genetic diversity within cancer genomes. A tumour arising in an individual heterozygous for a functional and a loss-of-function (LoF) allele of a gene occasionally retain only the LoF allel
Externí odkaz:
https://doaj.org/article/c93831231c574e67b595b2f52334f442
Publikováno v:
Cancer Nanotechnology, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract Background The addition of the cyclin dependent kinase inhibitor (CDKi) dinaciclib to Poly-(ADP-ribose) polymerase inhibitor (PARPi) therapy is a strategy to overcome resistance to PARPi in tumors that exhibit homologous recombination (HR) d
Externí odkaz:
https://doaj.org/article/bcb38076fd6e4bebba02ff716de87352
Autor:
Elizaveta Polyanskaya, Alexandra Lebedeva, Olesya Kuznetsova, Ekaterina Belova, Alexandra Kavun, Maxim Ivanov, Mikhail Fedyanin, Alexey Tryakin, Vladislav Mileyko, Dmitry Nosov
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Colorectal cancer (CRC) is currently one of the most common tumor types diagnosed worldwide. In the early stages, the disease responds well to surgical and chemotherapeutic treatment, but in the later stages when therapeutic options are exhausted, co
Externí odkaz:
https://doaj.org/article/1d2c8448ae5e4200969af1ec70e054f3
Autor:
Zahra Talebi, Dominique A. Garrison, Eric D. Eisenmann, Kalindi Parmar, Geoffrey I. Shapiro, Michelle A. Rudek, Alex Sparreboom, Yan Jin
Publikováno v:
Heliyon, Vol 9, Iss 11, Pp e20972- (2023)
A rapid, sensitive, and simple UHPLC-MS/MS method for the determination of the PARP inhibitor talazoparib in mouse plasma was developed and validated using [13C,2H4]-talazoparib as an internal standard (IS). The assay procedure involved extraction of
Externí odkaz:
https://doaj.org/article/17ba8d60031a4518b3675b5f4bdb071a
Publikováno v:
Опухоли женской репродуктивной системы, Vol 18, Iss 3, Pp 78-88 (2022)
Current clinical recommendations indicate the need for a biopsy of a metastatic focus in metastatic breast cancer (BC), but the optimal frequency of additional molecular analysis remains unclear. The discordance of hormonal receptors (HR) between the
Externí odkaz:
https://doaj.org/article/47724076f13b4d7cb602c36160806794
Autor:
Ticiana A. Leal, Marina N. Sharifi, Nancy Chan, Robert Wesolowski, Anita A. Turk, Justine Y. Bruce, Ruth M. O'Regan, Jens Eickhoff, Lisa M. Barroilhet, Jyoti Malhotra, Janice Mehnert, Eugenia Girda, Elizabeth Wiley, Natalie Schmitz, Shannon Andrews, Glenn Liu, Kari B. Wisinski
Publikováno v:
Cancer Medicine, Vol 11, Iss 21, Pp 3969-3981 (2022)
Abstract Background Inhibitors of poly(ADP‐ribose) polymerase (PARP) proteins potentiate antitumor activity of platinum chemotherapy. This study sought to determine the safety and tolerability of PARP inhibitor talazoparib with carboplatin and pacl
Externí odkaz:
https://doaj.org/article/d110893465fc4eceb9dd0c7b44d3c53f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.